Neurodegenerative disease management platform Octave Bioscience has now raised more than $48m in total, Blue Venture Fund and Echo Health Ventures backing its latest round.
Octave Bioscience, the US-based creator of a healthcare management platform neurodegenerative diseases, closed a $32m series B round yesterday featuring corporate venturing vehicles Blue Venture Fund and Echo Health Ventures.
The round was co-led by venture capital firm Northpond Ventures and healthcare investment firms Deerfield Management and Casdin Capital, and it included all the company’s existing backers.
Blue Venture Fund represents 36 BlueCross BlueShield health insurers and Echo Health Ventures was formed by healthcare provider Cambia Health Solutions and healthcare…
